TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) is now available.
EBR Systems, Inc. has received FDA approval for its WiSE System, supported by a Breakthrough Device Designation and compelling clinical data, positioning the company for significant growth. The company is launching a pilot program and plans a Limited Market Release in Q4 2025, supported by strong reimbursement strategies, including CMS-approved NTAP and TPT payments starting in October 2025, and is constructing a new manufacturing facility to support commercial growth, expected to be fully operational by mid-2026.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
EBR Systems, Inc. is a developer of the world’s first and only leadless pacemaker designed for heart failure, listed on the ASX since 2021 and registered with the SEC since 2024. The company focuses on a significant market opportunity in the US, targeting an initial addressable market of $3.6 billion with its unique WiSE System, which complements other cardiac pacing devices and is the only leadless device capable of pacing the left ventricle for heart failure.
Average Trading Volume: 707,235
Technical Sentiment Signal: Buy
Find detailed analytics on EBR stock on TipRanks’ Stock Analysis page.